NOTE: Please save this file locally before filling in the table, DO NOT work on the file within your internet browser as changes will not be saved. Adobe Acrobat Reader (available free here) is recommended for completion.

## **ARRIVE** The ARRIVE guidelines 2.0: author checklist

## The ARRIVE Essential 10

These items are the basic minimum to include in a manuscript. Without this information, readers and reviewers cannot assess the reliability of the findings.

	econ	nmendation	Section/line number, or reason for not reporting
Study design	1	For each experiment, provide brief details of study design including: a. The groups being compared, including control groups. If no control group has been used, the rationale should be stated.	Animal study design/ line 200-204
		b. The experimental unit (e.g. a single animal, litter, or cage of animals).	Animal study design/ line 200-204
Sample size	2	a. Specify the exact number of experimental units allocated to each group, and the total number in each experiment. Also indicate the total number of animals used.	Animal study design/ line 200-204
		b. Explain how the sample size was decided. Provide details of any <i>a priori</i> sample size calculation, if done.	Animal study design/ line 188-195
Inclusion and exclusion criteria	3 a	a. Describe any criteria used for including and excluding animals (or experimental units) during the experiment, and data points during the analysis. Specify if these criteria were	Animal study design/ line 196-199
		<ul><li>established a priori. If no criteria were set, state this explicitly.</li><li>b. For each experimental group, report any animals, experimental units or data points not included in the analysis and explain why. If there were no exclusions, state so.</li></ul>	Animals/ line 129-131
		c. For each analysis, report the exact value of <i>n</i> in each experimental group.	Animal study design/ line 201-205
Randomisation	4	a. State whether randomisation was used to allocate experimental units to control and treatment groups. If done, provide the method used to generate the randomisation sequence.	Animal study design/ line 201
		b. Describe the strategy used to minimise potential confounders such as the order of treatments and measurements, or animal/cage location. If confounders were not controlled, state this explicitly.	Animals/ line 210-213
Blinding	5	Describe who was aware of the group allocation at the different stages of the experiment (during the allocation, the conduct of the experiment, the outcome assessment, and the data analysis).	Animal study design/ line 205-206, 210
Outcome measures	6	a. Clearly define all outcome measures assessed (e.g. cell death, molecular markers, or behavioural changes).	Animal study design/ line 207-210 Animal study design/
		<ul> <li>b. For hypothesis-testing studies, specify the primary outcome measure, i.e. the outcome measure that was used to determine the sample size.</li> </ul>	line 192-194
Statistical methods	7	a. Provide details of the statistical methods used for each analysis, including software used	Statistical Analysis/ Line281-287
		b. Describe any methods used to assess whether the data met the assumptions of the statistical approach, and what was done if the assumptions were not met.	Statistical Analysis/ Line282-283
Experimental animals	8	<ul> <li>Provide species-appropriate details of the animals used, including species, strain and substrain, sex, age or developmental stage, and, if relevant, weight.</li> </ul>	Animals/ Line 129-130
		b. Provide further relevant information on the provenance of animals, health/immune status, genetic modification status, genotype, and any previous procedures.	Animals/ Line 129-130
Experimental procedures	9		Stroke modeling/ Line 216-225
		For each experimental group, including controls, describe the procedures in enough detail to allow others to replicate them, including:	Cell transplantation  Line 228-242
		a. What was done, how it was done and what was used.	MRI/
		b. When and how often.	MRI/ Line 251-259
		c. Where (including detail of any acclimatisation periods).	
		d. Why (provide rationale for procedures).	Immunohistochemistry  Line 262-278

Results	10		Results/ Line 291-336
		a. Summary/descriptive statistics for each experimental group, with a measure of variability where applicable (e.g. mean and SD, or median and range).	
		b. If applicable, the effect size with a confidence interval.	

## The Recommended Set

These items complement the Essential 10 and add important context to the study. Reporting the items in both sets represents best practice.

ltem	Recommendation	Section/line number or reason for not reporting
Abstract	11 Provide an accurate summary of the research objectives, animal species, strain and sex, key methods, principal findings, and study conclusions.	Abstract/ Line 30-53
Background	12 a. Include sufficient scientific background to understand the rationale and context for the study, and explain the experimental approach.	Introduction/ Line 56-126
	<ul> <li>Explain how the animal species and model used address the scientific objectives and, where appropriate, the relevance to human biology.</li> </ul>	
Objectives	13 Clearly describe the research question, research objectives and, where appropriate, specific hypotheses being tested.	Introduction/ Line 122-126
Ethical statement	14 Provide the name of the ethical review committee or equivalent that has approved the use of animals in this study, and any relevant licence or protocol numbers (if applicable). If ethical approval was not sought or granted, provide a justification.	Animals/ Line 150-152
Housing and husbandry	15 Provide details of housing and husbandry conditions, including any environmental enrichment.	Animals/ Line 131-146
Animal care and monitoring	16 a. Describe any interventions or steps taken in the experimental protocols to reduce pain, suffering and distress.	Animals/ Line 134-146
	b. Report any expected or unexpected adverse events.	
	c. Describe the humane endpoints established for the study, the signs that were monitored and the frequency of monitoring. If the study did not have humane endpoints, state this.	
Interpretation/ scientific implications	17 a. Interpret the results, taking into account the study objectives and hypotheses, current theory and other relevant studies in the literature.	Discussion/ Line 340-413
	b. Comment on the study limitations including potential sources of bias, limitations of the animal model, and imprecision associated with the results.	
Generalisability/ translation	18 Comment on whether, and how, the findings of this study are likely to generalise to other species or experimental conditions, including any relevance to human biology (where appropriate).	Discussion/ Line 410-413
Protocol registration	19 Provide a statement indicating whether a protocol (including the research question, key design features, and analysis plan) was prepared before the study, and if and where this protocol was registered.	Animals/ Line 150-151
Data access	20 Provide a statement describing if and where study data are available.	Availability of data and materials/ line 684-685
Declaration of interests	21 a. Declare any potential conflicts of interest, including financial and non-financial. If none exist, this should be stated.	Competing Interests/ Line 688
	b. List all funding sources (including grant identifier) and the role of the funder(s) in the design, analysis and reporting of the study.	Funding/ Line 692-694

